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Abstract
Background: IgA nephropathy has been reported as a renal involvement in Crohn’s disease. Crescentic IgA
nephropathy, which accounts for fewer than 5% of cases of IgA nephropathy, has a poorer prognosis than other
forms of crescentic glomerulonephritis. We recently experienced a case of rapidly progressive IgA nephropathy
concurrent with exacerbation of Crohn’s disease.
Case presentation: An 18-year-old male diagnosed with Crohn’s disease underwent a hemicolectomy 2 years prior
previously. He had maintained a state of Crohn’s disease remission with 5-aminosalicylic acid treatment. Four
months prior to referral to the nephrology clinic, he experienced non-bloody diarrhea. He simultaneously
developed proteinuria and microscopic hematuria with deterioration of renal function. Based on renal biopsy
findings, the patient was diagnosed with crescentic IgA nephropathy. Immunostaining for interleukin-17 in renal
tissue and previous exacerbated colonic ulcers was positive. Steroid pulse therapy was administered, followed by
high-dose glucocorticoid and oral cyclophosphamide therapy. The patient’s renal function recovered and his
gastrointestinal symptoms were alleviated.
Conclusions: We report a case of crescentic IgA nephropathy presenting with exacerbation of Crohn’s disease, and
present a review of the literature focusing on the pathophysiologic relationship between these two conditions.
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Background
Renal involvement, including tubulointerstitial nephritis,
amyloidosis, and urolithiasis caused by calcium oxalate
or urate, has been reported in approximately 4% to 23%
of patients with Crohn’s disease [1,2]. IgA nephropathy
(IgAN) is a renal disease associated with inflammatory
bowel diseases such as Crohn’s disease. Several cases of
IgAN accompanying Crohn’s disease have been reported
[3-7] in which patients developed proteinuria and
hematuria with or without mild deterioration of renal
function.
IgAN, a slowly progressive glomerular disorder, can
lead to end-stage renal disease within 20 years of diag-
nosis in up to 25% to 30% of patients with this condi-
tion. Although fewer than 5% of IgAN patients show
crescentic or rapidly progressive IgAN [8,9], crescentic
IgAN has a poorer prognosis than other forms of cres-
centic glomerulonephritis [9].
Crescentic IgAN has rarely been observed in patients
with Crohn’s disease. Here, we report a patient with rap-
idly progressive IgAN and exacerbation of Crohn’s dis-
ease. His intestinal symptoms and renal functions both
improved after the administration of immunosuppressive
agents. To better understand the pathogenesis, we also
review and summarize previous reports highlighting the
pathophysiological relationship between these two
conditions.
Case presentation
An 18-year-old male was referred to our nephrology
clinic for evaluation of azotemia and proteinuria in
March 2011. The patient had previously undergone an
operation to repair an anal fistula in December 2008 and
an appendectomy to treat acute appendicitis in January
2009 at a local clinic. He was admitted to our hospital in
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June 2009 due to right upper quadrant pain and bloody
diarrhea. Urinalysis revealed an absence of proteinuria
and microscopic hematuria. There was no deterioration
of renal function as determined by blood urea nitrogen
(BUN, 5.9 mg/dL) and serum creatinine (0.9 mg/dL)
analysis. Colonoscopic examination revealed linear, geo-
graphic ulcers with non-caseating granulomas in the dis-
tal ileum. The patient was diagnosed with Crohn’s
disease and treated with 3 g/day of 5-aminosalicylic acid
(5-ASA, mesalazine) and 9 mg/day of budesonide.
In July 2009, the patient visited the emergency room
with right lower quadrant pain, loose stool, and fever.
Simple abdominal X-ray showed free air below the dia-
phragm. He was diagnosed with an ascending colon
perforation and underwent an emergency right hemico-
lectomy. Budesonide administration was discontinued,
and the 5-ASA dosage was reduced to 2 g/day. The pa-
tient was additionally treated with ciprofloxacin (1 g/day)
and metronidazole (1.5 g/day), and was kept under ob-
servation for 2 weeks. After this time, he had intermittent
loose stools (0–2 times/day) without abdominal pain.
Next, the patient was given 5-ASA (2 g/day) as mainten-
ance therapy and his intestinal symptoms improved.
In December 2010, the patient experienced exacerba-
tion of his symptoms, with non-bloody diarrhea three to
four times daily. Colonoscopy revealed geographic ulcers
consistent with Crohn’s disease. His blood pressure was
127/76 mmHg. Laboratory test results showed normal
BUN (10.1 mg/dL) and serum creatinine (0.76 mg/dL)
levels. Although urinalysis revealed mild proteinuria (1+
according to a dipstick test) and microscopic hematuria,
the patient did not have a nephrology consultation. The
patient was treated with 5-ASA (1 g/day) and budeso-
nide (6 mg/day). After treatment, his abdominal pain
ceased and no more loose stools were experienced until
March 2011.
In March 2011, the patient experienced dark loose
stools three times daily, and developed pale conjunctiva.
He complained of facial puffiness and edema in his
lower extremities. His blood pressure was 137/96 mmHg.
Proteinuria (2+ by a dipstick test) and microscopic
hematuria were detected by urinalysis. His renal function
had deteriorated, with increased BUN (30.3 mg/dL) and
creatinine (3.42 mg/dL) levels. He was referred to a
nephrology clinic and admitted for evaluation.
His height was 170 cm and his body weight was 43 kg.
A 24-h urine study revealed the presence of proteinuria
(3,967 mg/day). Further serologic testing revealed a
mildly increased IgA level of 492 mg/dL (reference,
70–400 mg/dL) along with normal IgG (670 mg/dL;
reference, 700–1,600 mg/dL), IgM (55 mg/dL; reference,
40–230 mg/dL), C3 (126.7 mg/dL; reference, 90–180 mg/
dL), and C4 (40.5 mg/dL; reference, 10–40 mg/dL)
levels. Test results for anti-nuclear antibodies (ANA),
anti-neutrophil cytoplasmic antibodies (ANCA), anti-
glomerular basement membrane (anti-GBM) antibodies,
anti-streptolysin O (ASO) antibodies, rheumatoid factor
(RF), and cryoglobulin were all negative. Serologic tests
for hepatitis B, hepatitis C, and human immunodefi-
ciency viruses were also negative. Renal ultrasonographic
findings showed that the kidneys were normal-sized,
with increased cortical echogenicity.
Renal biopsy findings revealed nine crescent forma-
tions and eight scleroses in 17 glomeruli. Endocapillary
hypercellularity was also present. Inflammatory cells had
infiltrated into the interstitium. Mild tubular atrophy
with interstitial fibrosis was observed by light micros-
copy. In the mesangium, immunofluorescence assays
revealed 2+ diffuse fine granular staining for IgA and 1+
staining for IgM and C3. Electron microscopy revealed
dense deposits in the mesangial area (Figure 1A, B). The
patient was subsequently diagnosed with rapidly progres-
sive IgAN. Two days after the renal biopsy was performed,
serum creatinine levels increased from 3.9 mg/dL to
4.8 mg/dL. The patient was treated with prednisolone
pulse therapy (250 mg twice daily) for 3 consecutive days;
the dose was tapered to 1 mg/kg/day (Figure 2). Planned
intravenous cyclophosphamide therapy was canceled be-
cause the patient developed abdominal symptoms on the
fifth day of steroid treatment. He had watery diarrhea 10
times daily, and laboratory data revealed that he suffered
from metabolic acidosis caused by severe diarrhea. Blood
gas analysis showed the following parameters: pH 7.24,
PaCO2 22.4, PaO2 82.6, and HCO3 9.7. His serum chloride
level was 121 mmol/L; BUN and serum creatinine levels
were 89 and 3.88 mg/dL, respectively. The patient was
treated with 5-ASA (2 g/day) and loperamide (6 mg/day).
In addition, intravenous fluid therapy was administered
to restore volume loss. The watery diarrhea subsided
in 2 weeks, and the patient was discharged. He was
further treated at the outpatient department with oral
doses of deflazacort (48 mg/day) and cyclophospha-
mide (100 mg/day). In July 2011 (3 months after treat-
ment), these doses were tapered to 24 mg/day and
50 mg/day, respectively. 5-ASA dosage was maintained
at 2.0 g/day. The patient’s BUN level was 61.2 mg/dL,
and his serum creatinine concentration was 2.5 mg/dL.
Proteinuria was 2+ by dipstick test, and the spot urine
protein-creatinine ratio was 1.8 mg/g.
In September 2011, cyclophosphamide was replaced
with azathioprine (100 mg/day). One month later, the
patient was switched from azathioprine to mycopheno-
late sodium (360 mg/day) because of bone marrow sup-
pression. His intestinal symptoms were not aggravated,
and renal functions were also maintained (33.8 mg/dL
BUN and 2.32 mg/dL serum creatinine) while taking
mycophenolate sodium (360 mg/day) and deflazacort
(12 mg/day) during December 2011.
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To evaluate pathophysiological characteristics com-
mon for the exacerbation of Crohn’s disease and IgAN,
as well as possible mediators, we measured interleukin
(IL)-17 expression in renal and colon tissues from the
patient. We also compared renal IL-17 expression to
that in tissues from cases of primary IgAN without
Crohn’s disease. Immunostaining for IL-17 was positive
in both renal tissue and exacerbated colonic ulcers from
the patient (Figure 1C, D), in comparison, this staining
was negative in renal tissues from a patient with primary
IgAN (control; Figure 1E).
Conclusions
In this report, we presented a case of rapidly progressive
IgAN concurrent with aggravation of Crohn’s disease,
both of which responded to immunosuppressive
Figure 2 Clinical course and treatment of the patient.
Figure 1 Histological findings of the renal tissues and intestinal mucosa. Crescent formations of the glomeruli were observed with periodic
acid-Schiff (PAS) staining in light microscopy (A: 100× magnification). Immunofluorescence staining was positive for IgA in the mesangial regions
(B). Immunostaining for interleukin (IL)-17 was positive in renal tissue in April 2011 (C) and exacerbated colonic ulcer tissue (D) in December 2010.
IL-17 staining was negative in the primary IgA nephropathy (control) patient (E: 100× magnification).
Choi et al. BMC Nephrology 2012, 13:84 Page 3 of 5
http://www.biomedcentral.com/1471-2369/13/84
treatment. The association between IgAN and Crohn’s
disease is well established and increasingly reported in
the literature [4-7]. However, pathophysiological associ-
ation between the two diseases remains a matter of de-
bate. To our best knowledge, only one case of crescentic
IgAN in Crohn’s disease was previously reported, in
which acute renal failure occurred 8 weeks after recto-
sigmoid resection. Unlike the case detailed here, it did
not demonstrate a direct association between aggrava-
tion of renal function and concurrent intestinal symp-
toms [3]. IgAN, a type of glomerulonephritis that is
common in the general population, especially in Asian
populations, might be a coincidental pathology in a pa-
tient with Crohn’s disease. However, simultaneous ap-
pearance of clinical features of rapidly progressive IgAN
and aggravation of Crohn’s disease, as well as our
patient’s good response to therapy, suggest a common
underlying pathophysiology in both conditions. In
addition, in the detailed case, both renal and ulcerated
colonic tissue were positive for IL-17, which might
further support a potential common immunologic
mechanism.
IL-17, a cytokine produced by CD4+ memory T cells,
induces the release of pro-inflammatory cytokines from
monocytes and macrophages [10,11]. This soluble T cell
factor thereby promotes inflammation. Recently, IL-17
was identified as a novel immunoregulatory cytokine
involved in Crohn’s disease. Production of this factor is
significantly increased in the blood and intestinal mu-
cosa of patients with active Crohn’s disease [12]. More-
over, Lin et al. have demonstrated histologically that
tubular IL-17 expression is higher in IgAN patients than
in normal controls, and IgAN patients with higher IL-17
expression in tubular epithelial cells have reduced renal
function and more severe cases of proteinuria [13]. In
our patient, both renal tissues and exacerbated colonic
ulcers stained positive for IL-17. These first established
findings suggest that IL-17 activation may be involved
simultaneously in both aggravating intestinal inflamma-
tion and promoting the development of rapidly progres-
sive IgAN in patients with Crohn’s disease.
Several cases of IgAN in patients with Crohn’s disease
have suggested a possible pathophysiological relationship
between the two conditions. Increased intestinal perme-
ability has been observed in patients with both IgAN
and Crohn’s disease [14,15]. Altered intestinal perme-
ability may play a role in the pathogenesis of both dis-
eases by promoting the systemic influx of antigens as
well as immune complex formation and deposition.
Moreover, it has been established that CD4+ lympho-
cytes are predominant in the peripheral blood of patients
with Crohn’s disease [16] and the number of T alpha
cells possessing IgA-specific helper activity is increased
in patients with IgAN [17]. There is reasonable
consensus that abnormal T helper lymphocyte function
contributes to the pathogenesis of both diseases. In
addition, an association between HLA-DR1 and these
diseases has been demonstrated in patients [18,19],
which indicates the possible involvement of common
genetic factors.
It has been suggested that circulating immune com-
plexes containing IgA play a role in rapidly progressive
IgAN, and high levels of circulating immune complexes
correlate with the clinical activity and extent of glomeru-
lar crescent formation [20]. In this patient, the protein-
uria and azotemia intensified as his intestinal symptoms
were aggravated. It appears that loss of mucosal antigen
exclusion in Crohn’s disease led to increased immune
activation, resulting in pathogenic IgA production and
the aggravation of IgAN. These possible common
mechanisms are supported by a recurrent IgAN case
linked to the onset of Crohn’s disease [21]. Moreover, a
recent report showing steroid treatment for the bowel
disease resulted in both complete remission of Crohn’s
disease and improvements in renal function, proteinuria,
and hematuria, further supporting the hypothesis of a
common pathogenesis [5]. However, whether the clinical
activity of IgAN in patients with Crohn’s disease correlates
with the progression of gastrointestinal disease remains
uncertain. Lee et al. encountered a patient who had main-
tained remission of Crohn’s disease with 5-ASA and
azathioprine, but was diagnosed with IgAN [6]. In any
case, the possibility that primary unrelated IgAN deterio-
rates independent of coexistent Crohn’s disease or transi-
tions to a clinically evident disease during a relapse of
Crohn’s disease cannot be excluded. Additional studies are
needed to determine the causal relationship between the
two diseases.
Immunosuppressive agents, including high-dose corti-
costeroids and cyclophosphamide with or without
plasma exchange, are indicated for treating rapidly pro-
gressive glomerulonephritis. Regimens similar to those
recommended for renal vasculitis can reportedly help
preserve renal function [22]. Our patient was treated
with steroid pulse therapy followed by high doses of
steroids and oral cyclophosphamide. His renal function
gradually recovered with this regimen. His intestinal
symptoms also improved. Dabadie et al. reported a pa-
tient with Crohn’s disease showing clinical improvement
of gastrointestinal symptoms after receiving treatment
for IgAN [23]. Clinical improvement of both IgAN and
Crohn’s disease may be expected owing to common
pathophysiologic characteristics shared by these diseases.
The use of immunomodulatory agents may resolve
impaired T cell immunity and production of immune
complexes.
Crescentic IgAN has a poorer prognosis than other
forms of crescentic glomerulonephritis, even with
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immunosuppressive therapy. Renal survival rates among
crescentic IgAN patients are reportedly only 50% at
1 year and 20% at 5 years [9]. However, cases of rapidly
progressive IgAN in Crohn’s disease patients have rarely
been published [3]. Further analysis and follow-up of
more case series will provide information about the rela-
tionship between these diseases and renal survival.
In summary, we experienced a case of rapidly progres-
sive IgAN with exacerbation of Crohn’s disease. The pa-
tient responded well to immunosuppressive therapies.
Based on a literature review, we suggest that a variety of
mechanisms, including intestinal hyperpermeability, ab-
normal T helper lymphocyte function, and IL-17 activa-
tion, might be involved in the common pathogenesis of
these two diseases.
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